GlobeNewswire by notified

Karolinska Development’s portfolio company Svenska Vaccinfabriken presents scientific advancements at international conference

Share

STOCKHOLM, Sweden, June 27, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Svenska Vaccinfabriken has presented results from a preclinical study indicating that the company’s candidate therapeutic vaccine SVF-001 has potential to elicit an immune response in a disease model of chronic hepatitis B. The results were presented on June 25 at the EASL International Liver CongressTM 2022.

Svenska Vaccinfabriken develops therapeutic proteins and DNA vaccines targeting, among others, hepatitis B. Therapeutic vaccines have, in comparison to prophylactic vaccines, the potential to cure already infected patients. Chronic infections due to hepatitis B virus (HBV) is a key underlying factor to severe liver disease and cancer. Around 250 million people live with chronic hepatitis B today and due to the lack of curative therapies the need for effective treatments is large.

A hallmark of chronic hepatitis infections is the virus’s ability to evade the immune system. By interrupting the T-cell’s normal activity of seeking out and neutralizing the virus, tolerance is induced toward the virus and disease progression occurs. The recent study analyzed the immune response in a preclinical disease model of chronic hepatitis B following treatment with SVF-001. The results show that treatment generated a strong antibody response and high T-cell activity toward HBV. These positive data supports the further development of SVF-001.

"Hepatitis is a highly contagious infectious disease that affects both young and old worldwide and causes medical complications in both the short and long term. We are impressed by Svenska Vaccinfabriken and their innovative therapeutic vaccines that have the potential to address this widespread challenge, and we look forward to following the company's continued development," says Viktor Drvota, CEO of Karolinska Development.

Karolinska Development's ownership in Svenska Vaccinfabriken amounts to 34.8 percent.

Read the scientific abstract in its entirety (abstract code: SAT413): https://easl.eu/wp-content/uploads/2022/06/ILC-2022-Abstract-Book-15.06-Web.pdf

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Hoylu AB: Continued SaaS growth in July15.8.2022 08:30:00 CEST | Press release

Stockholm, Sweden, August 15, 2022 – Hoylu, a leader in visual collaboration solutions for distributed teams, today announced Annual Recurring Revenue (“ARR”) as of the end of July 2022. ARR, including long term mobile contracts, reached MSEK 48.5 as of the end of July 2022, up from MSEK 46.2 as of the end of June 2022. The report for July 2022 is attached to this press release and is available on Hoylu's web site: (https://www.hoylu.com/investor-relations/financial-reports/). For more information, please contact: Truls Baklid, CEO, +47 924 38 900 Email: tob@hoylu.com Karl Wiersholm, CFO, +1 425 829 2316 Email: kw@hoylu.com About Hoylu Hoylu's Adaptive Workspace opens up a new way for teams to plan, build and engage --so they get the impact they want no matter the industry, department or time. Whatever your management or planning style, Hoylu fits the way you structure your team and integrates all the productivity tools you're already using. So, you easily plan and complete any project

Expereo acquires Breeze Networks, further enhancing its SD-WAN/SASE practice and presence in the UK market15.8.2022 08:00:00 CEST | Press release

AMSTERDAM, Aug. 15, 2022 (GLOBE NEWSWIRE) -- The world’s leading provider of managed network solutions, Expereo, has announced the acquisition of Breeze Networks, a managed service provider of SD-WAN/SASE technologies. The acquisition fuels Expereo’s growth trajectory, further enhancing its SD-WAN/SASE practice, building on its expanding range of services to manage SD-WAN solutions at scale to partners and multinational enterprise customers across the globe. This latest acquisition solidifies Expereo’s ambition to complement its managed network solutions with world-class advisory practice providing guidance to organizations on their global transformation to software-defined and internet-based networking. With the full support of majority investor Vitruvian Partners and minority investor Apax Partners SAS, Expereo intends to continue its acquisition strategy. Breeze Networks is a managed service provider of cloud-based (SD-WAN) network connectivity and security solutions for enterprises

DNO Releases 2021 Corporate Social Responsibility Report15.8.2022 08:00:00 CEST | Press release

Oslo, 15 August 2022 – DNO ASA, the Norwegian oil and gas operator, today released its 2021 Corporate Social Responsibility Report. The report is attached as a downloadable file and is also available on the Company's website www.dno.no. – For further information, please contact: Media: media@dno.no Investors: investor.relations@dno.no – DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands and Yemen. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment 2021 CSR report

Sampo plc’s share buybacks 12/08/202215.8.2022 07:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 15/08/2022 at 08:30 am Sampo plc’s share buybacks 12/08/2022 On 12/08/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)14,42245.06AQEU29,72844.98CEUX9,01645.09TQEX76,83445.02XHELTOTAL130,00045.02 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 6,194,495 Sampo A shares representing 1.16 per cent of the total number of shares in Sampo plc. Details of ea

Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer15.8.2022 07:15:00 CEST | Press release

Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer1 Findings will be presented at an upcoming medical meeting Novartis remains committed to pursuing new therapeutic options that can have a meaningful impact on the lives of people with lung cancer Basel, August 15, 2022 — Novartis announced today that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1β), in adult patients with stages II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) did not meet its primary endpoint of disease-free survival (DFS) versus placebo1. No unexpected safety signals were observed.1 Findings from the trial will be presented at an upcoming medical meeting. “We made an investment in the CANOPY program based on signals of reduced lung cancer incidence and mortality observed in the CANTOS s